Characterization and Clinical Impact of the Gut Microbiota in Diffuse Large B-cell Lymphoma Patients
The study is a prospective observational single-center cohort study which compare the gut microbiome of newly diagnosed Diffuse Large B-cell Lymphoma patients with the gut microbiome of healthy controls. Furthermore the impact of lymphoma treatment, immune phenotypes, cytokine profiles, metabolomics, inflammation, driver mutations, comorbidity, body composition and lifestyle on the microbiome is also investigated
• WHO 2022 classified newly diagnosed and treatment-naïve large B-cell lymphoma (DLBCL) belonging to one of the following entities:
• Diffuse large B-cell lymphoma, including transformation from an indolent lymphoma
• Follicular lymphoma grade 3B
• T-cell/histiocyte-rich LBCL
• Primary cutaneous DLBCL, leg type
• EBV-positive DLBCL, NOS
• Primary mediastinal LBCL
• High grade B-cell lymphoma with MYC/BCL2 rearrangement
• The patient is a candidate for R-CHOP-like first-line treatment
• Staging by PET available before treatment initiation
• Age ≥18 years
• Written informed consent